NGM Biopharmaceuticals, Inc. (NGM) News
Filter NGM News Items
NGM News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest NGM News From Around the Web
Below are the latest news stories about NGM BIOPHARMACEUTICALS INC that investors may wish to consider to help them evaluate NGM as an investment opportunity.
Here's Why We're A Bit Worried About NGM Biopharmaceuticals' (NASDAQ:NGM) Cash Burn SituationThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although... |
NGM Bio Presents Positive Phase 2b Results from the ALPINE 4 Trial of Aldafermin in Patients with Compensated Cirrhosis (F4) Due to NASH at AASLD The Liver Meeting®--As previously reported, the ALPINE 4 study met its primary endpoint, with aldafermin 3 mg demonstrating a statistically significant reduction in Enhanced Liver Fibrosis (ELF) score compared to placebo after 48 weeks of treatment-- --ELF, an FDA-approved non-invasive blood test, can be used to predict liver-related events in patients with nonalcoholic steatohepatitis (NASH) and compensated cirrhosis-- --Dose-dependent improvements reported across histologic and multiple non-invasive secondary e |
NGM Bio to Participate in Upcoming Investor ConferencesSOUTH SAN FRANCISCO, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that David J. Woodhouse, Ph.D., Chief Executive Officer, will participate in a fireside chat at the upcoming 6th Annual Evercore ISI HealthCONx Conference and will present an overview of the company and provide a business update. Management will also be available |
NGM Biopharmaceuticals Inc (NGM) Reports Q3 2023 Financial ResultsCompany's net loss decreases year-over-year, cash runway extends into mid-2025 |
NGM Biopharmaceuticals (NGM) Reports Q3 Loss, Misses Revenue EstimatesNGM Biopharmaceuticals (NGM) delivered earnings and revenue surprises of 12.50% and 67.67%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock? |
NGM Bio Reports Third Quarter 2023 Financial Results and Provides Business Highlights--Jean-Frédéric Viret, Ph.D., has been appointed as Chief Financial Officer effective November 3, 2023-- --Continued to progress myeloid checkpoint solid tumor programs: NGM707, NGM831 and NGM438-- --Selected for an oral plenary presentation of data from Phase 2b ALPINE 4 trial of aldafermin in compensated cirrhosis (F4) due to NASH at upcoming AASLD The Liver Meeting®-- --Reported $166.0 million in cash, cash equivalents and marketable securities as of September 30, 2023, with expected cash run |
NGM Bio Announces Oral Plenary Presentation of Data from Phase 2b ALPINE 4 Trial of Aldafermin in Compensated Cirrhosis (F4) Due to NASH at Upcoming AASLD The Liver Meeting®SOUTH SAN FRANCISCO, Calif., Oct. 11, 2023 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that an abstract related to comprehensive results from the company’s Phase 2b ALPINE4 trial of aldafermin in patients with compensated cirrhosis (liver fibrosis stage 4, or, F4) due to nonalcoholic steatohepatitis (NASH) has been selected for an oral plenary pres |
Alexandria Real Estate Equities, Inc.'s One-of-a-Kind, Essential Labspace Platform Empowers the Integration and Enhancement of Biological Discoveries Enabled by AI to Widen the Opportunities for and Accelerate the Development of Novel MedicinesAlexandria Real Estate Equities, Inc. (NYSE: ARE), the first, preeminent, longest-tenured and pioneering owner, operator and developer of collaborative life science, agtech and advanced technology mega campuses in AAA innovation cluster locations, has been strategically developing and operating high-quality Labspace® infrastructure for, and investing in, some of the most advanced and innovative biopharmaceutical companies leveraging artificial intelligence (AI) and machine learning (ML) platform |
Strength Seen in Repare Therapeutics Inc. (RPTX): Can Its 12.2% Jump Turn into More Strength?Repare Therapeutics Inc. (RPTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term. |
Insiders Give Up US$292k As NGM Biopharmaceuticals Stock Drops To US$1.31Insiders who acquired US$462k worth of NGM Biopharmaceuticals, Inc.'s ( NASDAQ:NGM ) stock at an average price of... |